In a study, partial vs radical cytoreductive nephrectomy for clear cell metastatic renal cell carcinoma was associated with a 54% decreased risk for other-cause mortality.
A recent systematic review and meta-analysis provides the most up-to-date evidence for performance of triplet therapy compared with API-based doublets in mCSPC.